Patents by Inventor Steven Seaman

Steven Seaman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11851498
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: December 26, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, BioMed Valley Discoveries, Inc.
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Bradley St. Croix, Steven Seaman, Saurabh Saha, Xiaoyan Michelle Zhang, Gary A. DeCrescenzo, Dean Welsch
  • Publication number: 20230032465
    Abstract: An improved antibody-drug conjugate (ADC) targeting CD276-positive tumors is described. The ADC includes a CD276-specific IgG1 antibody having a heavy chain modified to prevent interaction of its Fc domain with endogenous Fc receptors and to introduce a cysteine for site-specific conjugation of the drug. The CD276-specific ADC is capable of potently eradicating CD276-positive tumors in several animal models.
    Type: Application
    Filed: December 8, 2020
    Publication date: February 2, 2023
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Brad St. Croix, Yang Feng, Steven Seaman
  • Publication number: 20200199246
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.
    Type: Application
    Filed: March 9, 2020
    Publication date: June 25, 2020
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Bradley St. Croix, Steven Seaman, Saurabh Saha, Xiaoyan Michelle Zhang, Gary A. DeCrescenzo, Dean Welsch
  • Patent number: 10604582
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: March 31, 2020
    Assignees: The United States Of America, as represented by The Secretary, Department of Health, Biomed Valley Discoveries, Inc.
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Bradley St. Croix, Steven Seaman, Saurabh Saha, Xiaoyan Michelle Zhang, Gary A. DeCrescenzo, Dean Welsch
  • Publication number: 20180186890
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric N antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.
    Type: Application
    Filed: September 16, 2015
    Publication date: July 5, 2018
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Bradley St. Croix, Steven Seaman, Saurabh Saha, Xiaoyan Michelle Zhang, Gary A. DeCrescenzo, Dean Welsch
  • Publication number: 20160194720
    Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.
    Type: Application
    Filed: November 30, 2015
    Publication date: July 7, 2016
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Brad St. Croix, Steven Seaman
  • Patent number: 8440411
    Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: May 14, 2013
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Brad St. Croix, Steven Seaman
  • Publication number: 20110207141
    Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.
    Type: Application
    Filed: March 21, 2011
    Publication date: August 25, 2011
    Inventors: Brad St. Croix, Steven Seaman
  • Publication number: 20100028256
    Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.
    Type: Application
    Filed: June 28, 2007
    Publication date: February 4, 2010
    Inventors: Brad St. Croix, Steven Seaman